Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel T cell immunotherapies. Their mission is to guide the immune system to overcome chronic infectious diseases and autoimmunity, ultimately improving patients' lives. They are focused on developing antigen-specific immunotherapies, leveraging the power of T cells to target specific diseases. The company's approach aims to either guide a patient's T cells to become regulatory T (Treg) cells that promote immune tolerance or effector T (Teff) cells that can be directed to eliminate virally infected or cancer cells.

Barinthus Biotherapeutics boasts a suite of proprietary technology platforms, including ChAdOx, MVA, and SNAP, which are designed to optimize the disease-fighting capabilities of T cells. These platforms have potential in multiple therapeutic areas, ranging from autoimmunity to chronic viral infections and cancer. The company has a strong management team with experience in all stages of immunotherapeutics research and development. They are headquartered in the UK, with office and research facilities in the US, and are publicly traded on the NASDAQ under the symbol BRNS.

Barinthus Biotherapeutics offers flexible work arrangements, allowing employees to balance their personal and professional lives. They embrace hybrid work models, enabling employees to work from both the office and home, and provide flexible hours to accommodate individual needs and commitments. This approach to work flexibility empowers employees to manage their time effectively and prioritize their well-being while contributing to the company's success.

Barinthus Biotherapeutics offers a competitive benefits package designed to attract and retain top talent. Employees enjoy comprehensive healthcare coverage, including medical, dental, and vision insurance, as well as a 401(k) retirement plan with a company match. In addition, employees receive generous paid time off, parental leave, and annual bonuses. The company also provides opportunities for professional development through training and education, as well as stock options.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies that guide the immune system to combat chronic infectious diseases and autoimmunity. Their mission is to leverage the power of T cells to create therapies that effectively control and potentially cure diseases, ultimately improving the lives of patients. They are driven by their commitment to patients and their families, as well as a strong belief in the potential of their technology to make a significant impact in the fight against these challenging conditions.

Barinthus Biotherapeutics fosters a collaborative and inclusive culture that values diversity, transparency, and employee growth. They promote a welcoming and friendly atmosphere where everyone feels valued and supported, with open communication and a flat structure that encourages all voices to be heard. They prioritize work-life balance through social events, team activities, and flexible work arrangements, while also supporting employees' professional development through mentorship, training programs, and annual L&D budgets.

Barinthus Biotherapeutics actively promotes diversity, equity, and inclusion throughout their organization. They believe that a diverse workforce is essential for driving innovation and success, and strive to create a welcoming and inclusive environment where all employees feel valued, respected, and empowered. They have implemented a Blind Recruiting policy to remove unconscious biases from the hiring process and have established a Business Resource Group to provide a platform for employees to advocate for initiatives close to their hearts. Their commitment to diversity is demonstrated in their leadership structure with two female members in their five-person C-suite, as well as a significant proportion of female leaders at Vice President and Director levels.